These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 1359615

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.
    Moore NA, Tye NC, Axton MS, Risius FC.
    J Pharmacol Exp Ther; 1992 Aug; 262(2):545-51. PubMed ID: 1354253
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
    Rasmussen K, Benvenga MJ, Bymaster FP, Calligaro DO, Cohen IR, Falcone JF, Hemrick-Luecke SK, Martin FM, Moore NA, Nisenbaum LK, Schaus JM, Sundquist SJ, Tupper DE, Wiernicki TR, Nelson DL.
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1265-77. PubMed ID: 16141369
    [Abstract] [Full Text] [Related]

  • 9. Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats. Characterization by the use of antagonists.
    Fuller RW, Snoddy HD.
    Neuropharmacology; 1984 Dec; 23(12A):1389-94. PubMed ID: 6527743
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents.
    Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL.
    Neuropsychopharmacology; 2003 Jan; 28(1):1-13. PubMed ID: 12496935
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Central serotonin antagonist activity of ketanserin.
    Fuller RW, Snoddy HD.
    Res Commun Chem Pathol Pharmacol; 1984 Oct; 46(1):151-4. PubMed ID: 6505385
    [Abstract] [Full Text] [Related]

  • 14. Discriminative stimulus control with olanzapine: generalization to the atypical antipsychotic clozapine.
    Porter JH, Strong SE.
    Psychopharmacology (Berl); 1996 Nov; 128(2):216-9. PubMed ID: 8956383
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The effects of metergoline and other serotonin receptor antagonists on serum corticosterone in rats.
    Fuller RW, Snoddy HD.
    Endocrinology; 1979 Oct; 105(4):923-8. PubMed ID: 477605
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067.
    Cohen ML, Fuller RW, Kurz KD, Parli CJ, Mason NR, Meyers DB, Smallwood JK, Toomey RE.
    J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.